Jazz Pharmaceuticals plc (JAZZ)
Automate Your Wheel Strategy on JAZZ
With Tiblio's Option Bot, you can configure your own wheel strategy including JAZZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JAZZ
- Rev/Share 68.5026
- Book/Share 65.2272
- PB 2.5589
- Debt/Equity 0.2735
- CurrentRatio 1.6516
- ROIC -0.0256
- MktCap 10142260780.0
- FreeCF/Share 22.02
- PFCF 7.5885
- PE -27.4931
- Debt/Assets 0.0953
- DivYield 0
- ROE -0.0925
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JAZZ | UBS | Buy | Neutral | -- | $188 | Nov. 24, 2025 |
| Initiation | JAZZ | Deutsche Bank | -- | Buy | -- | $152 | July 15, 2025 |
| Upgrade | JAZZ | UBS | Neutral | Buy | $145 | $179 | March 7, 2025 |
| Downgrade | JAZZ | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Feb. 26, 2025 |
| Upgrade | JAZZ | Wells Fargo | Equal Weight | Overweight | $130 | $170 | Feb. 13, 2025 |
| Upgrade | JAZZ | Morgan Stanley | Equal Weight | Overweight | $140 | $175 | Dec. 12, 2024 |
News
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.1 "This positive CHMP opinion is a welcome step for physicians and patients in Europe who …
Read More
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
Read More
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
ANET, GLW, JAZZ, AES and PPC are some of the stocks with high ROE to profit from as markets recoiled on tariff war.
Read More
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
4 Top PEG Stocks Based on GARP Approach to Smart Investing
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.
Read More
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Read More
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
Read More
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.
Read More
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Best Momentum Stocks to Buy for March 3rd
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
STRL. BATRA and JAZZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 3, 2025.
Read More
4 Stocks Trading Near 52-Week High With More Upside Potential
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Stocks like NFG, ENS, TAP and JAZZ are seeing price strength and have a high chance of carrying the momentum forward.
Read More
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise.
Read More
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Read More
Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.
Read More
About Jazz Pharmaceuticals plc (JAZZ)
- IPO Date 2007-06-01
- Website https://www.jazzpharma.com
- Industry Biotechnology
- CEO Renee D. Gala
- Employees 2800